Advertisement
Advertisement

SYBX

SYBX logo

Synlogic, Inc. Common Stock

1.07
USD
-0.09
-7.76%
Apr 04, 15:19 UTC -4
Closed
exchange

After-Market

1.07

0.00
0.00%

Synlogic, Inc. Common Stock Profile

About

Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts.

Info & Links

CEO

Mary Beth Dooley

Headquarters

P.O. Box 30
Winchester, MA 01890, UNITED STATES

Sector

Medical

Auditor

KPMG LLP

Share holders

67

Employees

1

Synlogic, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

12.51M

Enterprise Value

-6.35M

Enterprise Value/EBITDA(ttm)

0.16

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

5.15

Price to Book(mrq)

1.26

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

-98637.50%

Return on Equity(ttm)

-207.84%

Return on Invested Capital(ttm)

-175.70%

Return on Assets(ttm)

-114.81%

Income Statement

Revenue(ttm)

8.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

8.00K

EBITDA(ttm)3

-40.84M

Net Income Available to Common(ttm)

-23.36M

Diluted EPS(ttm)

-4.16

Share Statistics

Beta (5Y Monthly)

0.81

52-Week Change

-40.22%

S&P 500 52-Week Change

-2.50%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

11.70M

Dividend Yield

0.00%

Float4

11.34M

% Held by Insiders

3.02%

% Held by Institutions

63.40%

Balance Sheet

Total Cash(mrq)

18.86M

Total Cash Per Share(mrq)

1.61

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.80%

Quick Ratio(mrq)

2.71%

Book Value Per Share(mrq)

1.09

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.60

Free Cash Flow(ytd)

-30.34M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement